75999-61-0

Usage

Uses

Used in Pharmaceutical Research and Development:
2,2,2-Trifluoro-N-(4-isopropylphenyl)acetamide is used as a reagent for the synthesis of new drugs and as a building block in the production of various medical compounds. Its unique structure and properties make it a valuable component in the development of innovative pharmaceuticals.
Used as an Anticonvulsant and Analgesic Agent:
2,2,2-Trifluoro-N-(4-isopropylphenyl)acetamide has been studied for its potential as an anticonvulsant and analgesic agent, indicating its potential use in the treatment of epilepsy and pain management.
Used in Industrial Processes as a Stabilizer:
2,2,2-Trifluoro-N-(4-isopropylphenyl)acetamide is also used as a stabilizer in various industrial processes, contributing to the stability and quality of the end products.
Used in Pharmaceutical Production as a Solvent:
In the pharmaceutical industry, 2,2,2-Trifluoro-N-(4-isopropylphenyl)acetamide serves as a solvent in the production of pharmaceuticals, aiding in the manufacturing process and ensuring the quality of the final product.

Upstream product

• 99-88-7 4-Isopropylaniline 
• 407-25-0 trifluoroacetic anhydride 

Relevant academic research and scientific papers

HISTONE DEMETHYLASE INHIBITORS

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

Catalytic reduction of amides to amines by electrophilic phosphonium cations via FLP hydrosilylation

A catalytic methodology for the conversion of amides to amines is reported. Of the 25 examples described, 14 examples involve the reduction of N-trifluoroacetamides to the corresponding trifluoroethylamines. These reductions are achieved by catalytic hydrosilylation of the amide mediated by an electrophilic phosphonium cation (EPC) catalyst.

2-Trifluoromethyl-3-quinoline carboxamides, analgesic and anti-inflammatory compositions and methods employing them

Novel 3-quinoline carboxamides of the formula STR1 wherein X' is in the 5,6,7 or 8-position and is selected from the group consisting of hydrogen, halogen, straight or branched alkyl and alkoxy of 1 to 5 carbon atoms, --CF3, --SCF3 and --OCF3, R1 is selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, R2 ' is selected from the group consisting of thiazolyl, 4,5-dihydrothiazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, pyrimidyl and tetrazolyl, all optionally substituted with alkyl of 1 to 4 carbon atoms and phenyl optionally substituted with at least one member of the group consisting of alkyl and alkoxy of 1 to 4 carbon atoms, --CF3, --NO2 and halogen and their non-toxic, pharmaceutically acceptable acid addition salts having analgesic and anti-inflammatory activity and novel intermediates and process for their preparation.